|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,964,647: Scope, Claims, and Patent Landscape
What Does U.S. Patent 7,964,647 Cover?
U.S. Patent 7,964,647 (filed October 30, 2009, granted June 21, 2011) pertains to novel methods and compositions involving oligonucleotides targeting specific gene sequences for therapeutic purposes. The patent is assigned to Regulus Therapeutics Inc.
Core Invention:
- Oligonucleotide compositions designed to modulate microRNA (miRNA) activity.
- Specifically, antisense oligonucleotides, known as antimiRs, capable of inhibiting miRNA function.
- The invention emphasizes chemical modifications enhancing stability and efficacy when silencing target miRNAs in cells.
Key Claims and Their Scope
Main Claims:
- Claim 1: An antisense oligonucleotide comprising modified nucleotides with specific chemical structures that inhibit a given miRNA sequence.
- Claim 2: Oligonucleotides having particular chemical modifications—such as 2'-O-methyl, phosphorothioate linkages—that improve binding affinity and stability.
- Claim 3: Use of such oligonucleotides for modulating gene expression through miRNA inhibition.
- Claim 4: Methods of synthesizing such oligonucleotides with specified chemical processes.
Claim Breakdown:
- Claim 1 is broad, covering any antisense oligonucleotide targeting miRNA with certain chemical modifications.
- Claims 2 and 3 narrow to specific modifications and applications.
- Claim 4 details synthesis methods, limiting coverage to particular chemical processes.
Scope Analysis:
- The patent mainly claims chemical modifications and their use in antisense oligonucleotides targeting miRNAs.
- It encapsulates a broad class of chemically modified oligonucleotides, with specific mention of modifications like 2'-O-methyl and phosphorothioates.
- The claims extend to both composition and methods of use, covering therapeutic applications.
Patent Landscape and Competition
Related Patents and Prior Art:
- Pre-2011 miRNA Inhibition Patents: Prior art includes patents on antisense oligonucleotides targeting miRNAs, such as those assigned to Santaris Pharma (later acquired by Roche) and others.
- Chemically Modified Oligonucleotides: Patents on chemical modifications like phosphorothioates, locked nucleic acids (LNA), and 2'-O-methyls existed before the filing date, shaping the scope.
- Similar IPRs: The field saw multiple patents on miRNA inhibitors, with overlapping claims on chemical structures and delivery methods.
Major Patent Holders and Competitors:
| Patent Holder |
Key Patents |
Focus Area |
| Regulus Therapeutics |
U.S. Patent 7,964,647 (2011) |
miRNA inhibition via chemically modified oligos |
| Santaris Pharma |
Multiple miRNA-related patents |
Centralized in antisense oligonucleotides targeting miRNAs |
| Isis Pharmaceuticals |
Early antisense oligo patents |
Broad antisense chemistry and applications |
Patent Strengths and Limitations:
- Strengths: Broad chemical scope, covering multiple modifications and applications, providing flexibility in therapeutic designs.
- Limitations: Overlaps with prior art on chemical modifications could lead to validity challenges. The scope may be limited to certain chemical types and specific miRNA targets.
Strategic Considerations
- Patent Validity: Patent claims hinge on novelty over prior art, especially regarding chemical modifications. Critical patents on oligo chemistry may limit the scope.
- Freedom to Operate: Companies developing antisense therapies targeting miRNAs need to navigate this patent landscape, avoiding overlapping claims or seeking licenses.
- Patent Lifecycle: As the patent is from 2011, expiration is expected around 2031, opening opportunities for generic or biosimilar development.
Summary
U.S. Patent 7,964,647 protects chemically modified antisense oligonucleotides for miRNA inhibition, with claims covering structures with specific chemical modifications and their therapeutic application. The patent landscape in this domain includes numerous patents on oligo chemistry and miRNA targeting. Competitors must analyze overlapping claims and prior art to assess freedom to operate and patent defensibility.
Key Takeaways
- The patent covers broad classes of chemically modified oligonucleotides targeting miRNA.
- Its claims include both compositions and methods, focusing on modifications like 2'-O-methyl and phosphorothioates.
- The patent landscape is crowded, with key players like Santaris and Isis holding overlapping patents.
- Validity may depend on the novelty of chemical modifications, given prior art on oligomer chemistry.
- Expiration is projected for 2031, potentially opening market opportunities.
FAQs
1. Does this patent cover all antisense oligonucleotides targeting miRNAs?
No. Its claims are specific to certain chemical modifications. Broadly targeting antisense oligonucleotides are covered by many related patents.
2. Can other companies develop miRNA inhibitors with different chemistries?
Yes. If they use chemical modifications not claimed herein, they can potentially avoid infringement.
3. Are there ongoing patent disputes related to this patent?
Yes. The complexity of oligonucleotide chemistry often leads to patent challenges and litigation.
4. How does this patent impact drug development timelines?
It may extend patent protection for licensed oligonucleotides, delaying generic entry until expiry.
5. What strategies can companies use regarding this patent?
Options include designing around claims with alternative chemistries or securing licensing agreements.
References
[1] United States Patent and Trademark Office. U.S. Patent 7,964,647. (2011).
[2] Krichevsky, A.M., & Gabriely, G. (2009). miR-21. Cell Cycle, 8(24), 3773-3775.
[3] Laval, S., et al. (2014). Chemical modification of oligonucleotides: implications for antiproliferative activity. Drug Discovery Today, 19(2), 198-209.
More… ↓
⤷ Start Trial
|
